Disulfiram and cancer immunotherapy: Advanced nano-delivery systems and potential therapeutic strategies

• Egile Nagusiak: Di Huang (Egilea), Yinsha Yao (Egilea), Yifei Lou (Egilea), Longfa Kou (Egilea), Qing Yao (Egilea), Ruijie Chen (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2024-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

The initial focus of the clinical application of disulfiram was its efficacy in treating alcoholism. However, recent research has revealed its potential as an anti-tumor agent and even as an enhancer of cancer immunotherapy. Disulfiram has received safety approval from the FDA, indicating its safety...